TBPH icon

Theravance Biopharma
TBPH

Overview Fund Activity

120 hedge funds and large institutions have $600M invested in Theravance Biopharma in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
120
Holders Change
+5
Holders Change %
+4.35%
% of All Funds
1.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
43
Reduced
38
Closed
14
Calls
$1.49M
Puts
$5.71M
Net Calls
-$4.22M
Net Calls Change
-$1.06M

Top Buyers

1
WAM
1
Weiss Asset Management
Massachusetts
$51.7M
2
WP
2
Woodline Partners
California
$12.7M
3
Vanguard Group
3
Vanguard Group
Pennsylvania
$66.4M
4
Goldman Sachs
4
Goldman Sachs
New York
$9.34M
5
Bank of America
5
Bank of America
North Carolina
$6.4M

Top Sellers

1
O
1
OrbiMed
New York
$31.1M
2
Morgan Stanley
2
Morgan Stanley
New York
$6.41M
3
TCM
3
Tekla Capital Management
Massachusetts
$0
4
CCM
4
Camber Capital Management
Massachusetts
$0
5
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$628K
Name Holding Trade Value Shares
Change 		Shares
Change %
JF
126
Jump Financial
Illinois
– -$131K -11,900 Closed
Mirae Asset Global Investments
127
Mirae Asset Global Investments
South Korea
– -$110K -10,022 Closed
CG
128
Cutler Group
California
– -$95K -8,623 Closed
PA
129
Parallel Advisors
California
– -$21K -1,899 Closed
Rockefeller Capital Management
130
Rockefeller Capital Management
New York
– -$6K -625 Closed
PCG
131
Private Capital Group
Connecticut
– -$2K -136 Closed
2 3 4 5
6